Pharming Group is a biopharmaceutical company focused on rare diseases, best known for RUCONEST, a recombinant C1 esterase inhibitor used for acute hereditary angioedema attacks. It has expanded into other rare immunology indications, including leniolisib (Joenja) for activated PI3K delta syndrome (APDS). The model combines in-house commercialization in key markets with partnerships and a specialty-rare-disease commercial footprint.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 93.2 | — | 4.7 | — |
| Q3 2025 | 97.3 | — | 7.5 | — |
| Q4 2025 | 106.5 | — | 5.3 | — |
| Q1 2026 | 72.5 | — | -5.2 | — |
| Q2 2026 | 90.2 | -3.2% | 1.6 | -65.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Immix Biopharma, Inc. (IMMX), Alpha and Omega Semiconductor Limited (AOSL), Achieve Life Sciences, Inc. (ACHV), Starling Oncology, Inc. (STLN), Thornburg Income Builder Opportunities Trust (TBLD), Legacy Housing Corporation (LEGH)